RLAY logo

Relay Therapeutics, Inc. Common Stock


RLAY: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).


Show RLAY Financials

Consumer Interest
SEC Filings

Recent trades of RLAY by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by RLAY's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Dec. 20, 2022
  • Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Mar. 02, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of RLAY in WallStreetBets Daily Discussion


Recent insights relating to RLAY

CNBC Recommendations

Recent picks made for RLAY stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RLAY

Corporate Flights

Flights by private jets registered to RLAY